- Cyclacel Pharmaceuticals (CYCC) prices its public offering of 2,857,143 shares of common stock at $3.50/share. Gross proceeds will be ~$10M and will be used to fund the continued development of sapacitabine and general corporate purposes.
- Underwriters over-allotment is 428,571 shares.
- Closing date is April 9.
- Shares closed yesterday at $3.71.
- 17 mutual funds have positions, down from 20 a year earlier.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs